Sitagliptin -- the diabetic drug opportunity is being chased by many players in the market today. Who gets into the doctor’s pen first and manages to stay for a long time is something one should wait and watch to see. Almost all therapies and the majority of the market players have shown a strong positive value and volume growth.
Sitagliptin has a strong clinical profile and the potential to revolutionise the treatment of type 2 diabetes for millions of people who do not achieve the targeted blood sugar level with currently available anti-diabetic medications.
According to 2019 estimates, 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045. Diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by the disease in 2019.
The drug is an oral solution that works in type 2 diabetes mellitus patients by slowing the inactivation of incretin hormones.
Sitagliptin and its fixed-dose combinations support the heart and kidneys by protecting beta cells and are safe for older individuals and those with kidney or liver ailments.
Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate)
Mumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal valued at more than Rs. 200 crore.
Medicines worth Rs 30 lakh seized from raids on firms in Mumbai, Navi Mumbai.
The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market sitagliptin and metformin hydrochloride in the strength of 50mg/500 mg and 50mg/1000 mg, Cadila Healthcare said in a BSE filing.
"I see the progress made by the Modi administration towards not only ensuring that India can meet the needs of its people in healthcare, but also progress in a global environment of innovations."
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
